The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 331:1021-1022 October 13, 1994 Number 15
NextNext

Treatment of the Serotonin Syndrome with Cyproheptadine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: The serotonin syndrome consists of behavioral, neuromuscular, and autonomic changes that result from increased activity of serotonin (5-hydroxytryptamine) in the central nervous system.1 Its symptoms and signs include confusion, fever, diaphoresis, hyperreflexia, ataxia, and myoclonus. The syndrome usually results from the concurrent use of two serotonergic medications, most often a monoamine oxidase inhibitor and either tryptophan or an inhibitor of serotonin reuptake, such as fluoxetine (Prozac) or sertraline (Zoloft). Because of the long-lasting serotonergic activity of both monoamine oxidase inhibitors and inhibitors of serotonin reuptake, however, the syndrome can occur when one drug is discontinued and the . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.